Charles Schwab
MRNS

Charles Schwab’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Charles Schwab’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-154,667
Closed -$1.4M – 3717
2024
Q1 		$1.4M Buy
154,667
+5,241
+4% +$50.9K ﹤0.01% 2697
2023
Q4 		$1.62M Buy
149,426
+10,497
+8% +$78.7K ﹤0.01% 2676
2023
Q3 		$1.12M Buy
138,929
+3,864
+3% +$32.1K ﹤0.01% 2762
2023
Q2 		$1.47M Buy
135,065
+115,496
+590% +$989K ﹤0.01% 2646
2023
Q1 		$135K Sell
19,569
-5,091
-21% -$31.9K ﹤0.01% 3213
2022
Q4 		$98.1K Buy
24,660
+11,851
+93% +$58.3K ﹤0.01% 3262
2022
Q3 		$86K Hold
12,809
– – ﹤0.01% 3238
2022
Q2 		$62K Sell
12,809
-82,238
-87% -$500K ﹤0.01% 3362
2022
Q1 		$889K Buy
95,047
+2,281
+2% +$22.7K ﹤0.01% 2903
2021
Q4 		$1.1M Hold
92,766
– – ﹤0.01% 2871
2021
Q3 		$1.06M Buy
92,766
+1,721
+2% +$23.7K ﹤0.01% 2858
2021
Q2 		$1.63M Buy
91,045
+16,213
+22% +$261K ﹤0.01% 2785
2021
Q1 		$1.16M Buy
74,832
+13,412
+22% +$194K ﹤0.01% 2810
2020
Q4 		$750K Buy
61,420
+3,954
+7% +$55.1K ﹤0.01% 2864
2020
Q3 		$739K Buy
57,466
+6,241
+12% +$53.9K ﹤0.01% 2761
2020
Q2 		$521K Buy
51,225
+2,060
+4% +$18.9K ﹤0.01% 2814
2020
Q1 		$400K Buy
49,165
+17,475
+55% +$151K ﹤0.01% 2790
2019
Q4 		$274K Hold
31,690
– – ﹤0.01% 2994
2019
Q3 		$196K Hold
31,690
– – ﹤0.01% 3042
2019
Q2 		$527K Buy
31,690
+7,815
+33% +$136K ﹤0.01% 2787
2019
Q1 		$400K Buy
23,875
+4,525
+23% +$65.2K ﹤0.01% 2842
2018
Q4 		$223K Hold
19,350
– – ﹤0.01% 3004
2018
Q3 		$774K Buy
19,350
+2,400
+14% +$68.3K ﹤0.01% 2702
2018
Q2 		$480K Buy
+16,950
New +$376K ﹤0.01% 2819

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's MRNS Position: Q2 2024 in Review

Charles Schwab sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 154,667 shares — an estimated $1.4M sold.

Charles Schwab first reported a position in MRNS in Q2 2018 and held it in 24 quarters. The position peaked at $1.63M in Q2 2021. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Charles Schwab reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Charles Schwab sold 154,667 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $1.4M.
  • Charles Schwab first reported a position in Marinus Pharmaceuticals, Inc in Q2 2018 and held it in 24 quarters.
  • Charles Schwab's Marinus Pharmaceuticals, Inc position peaked at $1.63M in Q2 2021.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.